Yahoo!
My Yahoo!
Mail
Sign In
[New User?
Sign Up
]
Finance Home
|
Help
Wednesday, February 10, 2010, 8:35am EST - Canadian Markets open in 55 minutes.
To create a watchlist or portfolio of shares,
Sign-in
or
Register
Finance Home
Investing
Volume Leaders
Local Markets
US Markets
International Markets
Advances & Declines
ETFs
Income Trust News
News & Opinion
Markets
Industry
RSS-My Yahoo!
Personal Finance
Banking & Budgeting
Calculators
Insurance
Retirement
Taxes
My Portfolios
Sign In to Create/Edit My Portfolios
Get Quotes
Symbol Lookup
Exchanges
Antigenics Inc. (AGEN)
On Feb 9:
0.735 USD
0.00 (0.00%)
MORE ON AGEN
Quotes
Summary
Options
Historical Prices
Charts
Interactive
Basic Chart
Technical Chart
News & Info
Headlines
Company Events
Company
Profile
Key Statistics
SEC Filings
Competitors
Industry
Analyst Coverage
Analyst Opinion
Analyst Estimates
Research Reports
Star Analysts
Ownership
Major Holders
Insider Trans.
Insider Roster
Financials
Income Statement
Balance Sheets
Cash Flow
Antigenics Inc.
(NCM:AGEN) Delayed quote data
Last Trade:
0.735 USD
Trade Time:
Feb 9
Change:
0.00 (0.00%)
Prev Close:
0.735
Open:
N/A
Bid:
0.71
x 2100
Ask:
0.78
x 300
1y Target Est:
3.40
Day's Range:
N/A - N/A
52wk Range:
0.27 - 3.34
Volume:
0
Avg Vol
(3m)
:
912,554
Market Cap:
65.96M
P/E
(ttm)
:
N/A
EPS
(ttm)
:
-0.366
Div & Yield:
N/A (N/A%)
1d
5d
3m
6m
1y
2y
5y
max
Add AGEN to Portfolio
Download Data
HEADLINES
Antigenics Files $100 Million Mixed Shelf: BioBuzz
at TheStreet.com
(Mon, Jan 25)
New Gold, Poniard: Early Volume Plays
at TheStreet.com
(Mon, Jan 25)
ANTIGENICS INC /DE/ Files SEC form 8-K, Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standar
EDGAR Online
(Thu, Dec 31)
Antigenics Receives NASDAQ Delisting Notification
Business Wire
(Thu, Dec 31)
Mentor Capital Cancer Vaccine Investing Update
at Seeking Alpha
(Wed, Dec 23)
Biotech Stock Mailbag: Year in Review
at TheStreet.com
(Fri, Dec 18)
Antigenics pulls European Oncophage application
AP
(Fri, Nov 20)
ANTIGENICS INC /DE/ Files SEC form 8-K, Regulation FD Disclosure, Financial Statements and Exhibits
EDGAR Online
(Fri, Nov 20)
European CHMP Formally Adopts Negative Opinion on Oncophage®
Business Wire
(Fri, Nov 20)
ANTIGENICS INC /DE/ Financials
EDGAR Online Financials
(Fri, Nov 13)
ANTIGENICS INC /DE/ Files SEC form 10-Q, Quarterly Report
EDGAR Online
(Mon, Nov 9)
More Headlines for AGEN...
ANALYST
EPS Est (next year)
(Dec-09)
:
-0.52
EPS Est (in 2 years)
(Dec-10)
:
-0.36
Avg Rec (current)*:
3.0
PEG Ratio:
N/A
* (Strong Buy) 1.0 - 5.0 (Strong Sell)
Analyst Opinion
-
Estimates
BUSINESS SUMMARY
Antigenics Inc., a biotechnology company, engages in developing and commercializing technologies to treat cancers and infectious diseases, primarily based on immunological approaches.
Full Company Profile
Add to Portfolio
Email to a Friend
Get
Summary
for Another Symbol:
Symbol Lookup
Latest News
Canadian Indices